5 research outputs found
High frequency:Low frequency ratios over time.
<p>(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.</p
Serious: Non-serious ratios over time.
<p>(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.</p
The 5 Drugs Studied.
<p>*ADR: adverse drug reaction, EPPV: early post-marketing phase vigilance.</p><p>The 5 Drugs Studied.</p
High prominence:Low prominence ratios over time.
<p>(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.</p
Adverse drug reaction reporting trend for 5 drugs.
<p>Total number of individual case safety reports for (A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.</p